Multiple Sclerosis
RSSArticles
-
Disease Rebound After Stopping Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis
A review of patients with relapsing-remitting multiple sclerosis who discontinued fingolimod therapy showed that five out of 46 (10.9 %) of these patients developed a rebound phenomenon between 4 to 16 weeks, where disease activity returns and often exceeds pre-treatment levels.
-
Biomarkers of Intrathecal Inflammation in Multiple Sclerosis and Other Disorders
A study of intrathecal immune markers in neuro-immunological diseases revealed increased numbers of activated T and B cells in both relapsing and progressive multiple sclerosis, but they were preferentially embedded in the brain tissue in progressive multiple sclerosis.
-
Autologous Hematopoietic Stem Cell Transplant for Relapsing-Remitting MS
Interim analysis at 3 years post-treatment of a study of high-dose immunosuppression and autologous hematopoietic stem cell transplant for relapsing remitting-multiple sclerosis demonstrates sustained disease control but also shows potential risks associated with this treatment.
-
Is Pediatric-onset Multiple Sclerosis a Neurodegenerative Disorder?
ABSTRACT & COMMENTARY: Pediatric-onset multiple sclerosis compromises age-expected brain growth.
-
When Is it Best to Evaluate the Results of a CSF Tap Test?
The tap test has variable results as a tool to assess patients with a presumed diagnosis of normal pressure hydrocephalus. -
Rituximab May Be Effective for Refractory Myasthenia Gravis
In a restrospective review, rituximab appeared beneficial for patients with medication-resistant myasthenia gravis. -
Pharmacology Watch
New recommendations for HPV vaccine; guidelines for treatment of essential tremor; updates on smoking cessation drugs; and FDA actions. -
Stroke Alert: A Review of Current Clinical Stroke Literature
Forty-nine clinical centers and 18 positron emission tomography (PET) centers in the United States and Canada participated in a randomized, blinded-adjudication clinical treatment trial of 195 patients with symptomatic atherosclerotic internal carotid artery occlusion (AICAO) who also had hemodynamic cerebral ischemia identified by ipsilateral increased oxygen extraction fraction measured by PET. -
Clinical Briefs in Primary Care Supplement
-
Teriflunomide: A New Oral Agent for the Treatment of Multiple Sclerosis
Teriflunomide, an orally administered inhibitor of dihydro-orotate dehydrogenase, was found to be superior to placebo in reducing relapses in a 2-year, Phase 3 clinical trial in patients with multiple sclerosis.